Acumen Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Acumen Pharmaceuticals
ABOS Stock  USD 2.20  0.16  6.78%   
Acumen Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Acumen Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Acumen Pharmaceuticals financial statements helps investors assess Acumen Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Acumen Pharmaceuticals' valuation are summarized below:
Gross Profit
-32.4 M
Market Capitalization
135.8 M
Enterprise Value Revenue
89.674
Revenue
329 K
Earnings Share
(1.38)
There are over one hundred ten available fundamental signals for Acumen Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Acumen Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 239.5 M in 2024. Enterprise Value is likely to drop to about 97.5 M in 2024
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 8.6 M, Interest Income of 8.6 M or Depreciation And Amortization of 174.8 K, as well as many indicators such as Price To Sales Ratio of 415, Dividend Yield of 0.0 or PTB Ratio of 0.73. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Acumen Pharmaceuticals Correlation against competitors.
For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

Acumen Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets173.5 M310.1 M68.5 M
Slightly volatile
Other Current Liabilities5.9 M9.9 M2.9 M
Slightly volatile
Total Current Liabilities7.4 M13 M3.5 M
Slightly volatile
Accounts Payable1.1 M1.4 M529.2 K
Slightly volatile
Cash81.3 M66.9 M34 M
Slightly volatile
Non Currrent Assets Other476.7 K454 K170 K
Slightly volatile
Cash And Short Term Investments146.5 M243.5 M58.1 M
Slightly volatile
Common Stock Shares Outstanding46.2 M48.6 M41.2 M
Slightly volatile
Liabilities And Stockholders Equity173.5 M310.1 M68.5 M
Slightly volatile
Non Current Liabilities Total17.6 M30.2 M18.9 M
Very volatile
Inventory52.4 K98 K48.8 K
Very volatile
Other Current Assets2.4 M2.9 M1.2 M
Slightly volatile
Total Liabilities22.1 M43.2 M21.9 M
Pretty Stable
Total Current Assets149 M246.6 M59.4 M
Slightly volatile
Net Working Capital141.6 M233.6 M55.8 M
Slightly volatile
Short and Long Term Debt Total29.9 M28.5 M4.1 M
Slightly volatile
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Capital Surpluse392.1 M413.9 M360.1 M
Slightly volatile
Short Term Debt1.8 M1.7 M361.9 K
Slightly volatile
Common Stock5.1 K6 K4.2 K
Slightly volatile
Property Plant Equipment110.5 K189.8 K59.8 K
Slightly volatile
Long Term Debt21.9 M24.6 M26.8 M
Slightly volatile

Acumen Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income8.6 M8.2 M1.3 M
Slightly volatile
Interest Income8.6 M8.2 M1.3 M
Slightly volatile
Depreciation And Amortization174.8 K184 K660.9 K
Pretty Stable
Selling General Administrative19.8 M18.8 M4.6 M
Slightly volatile
Other Operating Expenses31.9 M61.1 M17.5 M
Slightly volatile
Research Development22.8 M42.3 M13.6 M
Slightly volatile
Cost Of Revenue44.4 M42.3 M5.8 M
Slightly volatile
Total Operating Expenses31.9 M61.1 M17.5 M
Slightly volatile
Selling And Marketing Expenses147.2 K165.6 K180.3 K
Slightly volatile

Acumen Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.5 M6.1 M1.2 M
Slightly volatile
Change In Working Capital2 M3.9 M1.2 M
Slightly volatile
Begin Period Cash Flow68.1 M130.1 M29.5 M
Slightly volatile
Depreciation193.2 K184 K39.6 K
Slightly volatile
Capital Expenditures19.9 K21 K45.5 K
Pretty Stable
Issuance Of Capital Stock83.5 M126.1 M34.6 M
Slightly volatile
Total Cash From Financing Activities89.5 M151.8 M36.8 M
Slightly volatile
End Period Cash Flow81.3 M67.1 M34 M
Slightly volatile
Change To Liabilities3.1 M2.9 M704 K
Slightly volatile
Sale Purchase Of Stock3.3 M3.5 M137.1 M
Slightly volatile
Cash And Cash Equivalents Changes6.8 M7.1 M64.2 M
Slightly volatile
Cash Flows Other Operating1.3 M1.4 M62.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio415506491
Slightly volatile
Days Sales Outstanding13.6624.9312.4155
Slightly volatile
Stock Based Compensation To Revenue0.080.09650.1016
Slightly volatile
Capex To Depreciation0.110.11410.8406
Slightly volatile
EV To Sales401478479
Pretty Stable
Payables Turnover32.2230.68754.2276
Slightly volatile
Sales General And Administrative To Revenue0.590.850.6479
Slightly volatile
Research And Ddevelopement To Revenue4.255.015.1002
Very volatile
Cash Per Share5.275.0221.4792
Slightly volatile
Days Payables Outstanding11.311.89418.4 K
Slightly volatile
Income Quality0.810.82230.8181
Pretty Stable
Current Ratio14.8819.012810.4026
Slightly volatile
Receivables Turnover14.3915.1542.3153
Slightly volatile
Graham Number7.6811.56674.3824
Slightly volatile
Debt To Equity0.110.10560.0149
Slightly volatile
Capex Per Share4.0E-44.0E-40.0011
Pretty Stable
Revenue Per Share0.04290.04110.0409
Slightly volatile
Interest Debt Per Share0.610.58160.0817
Slightly volatile
Debt To Assets0.09550.09090.0129
Slightly volatile
Days Of Payables Outstanding11.311.89418.4 K
Slightly volatile
Long Term Debt To Capitalization0.07430.08360.091
Slightly volatile
Total Debt To Capitalization0.10.09550.0135
Slightly volatile
Debt Equity Ratio0.110.10560.0149
Slightly volatile
Quick Ratio14.8819.012810.4026
Slightly volatile
Net Income Per E B T0.950.851.0329
Pretty Stable
Cash Ratio9.175.15667.3609
Slightly volatile
Days Of Sales Outstanding13.6624.9312.4155
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00051.0088
Slightly volatile
Debt Ratio0.09550.09090.0129
Slightly volatile
Price Sales Ratio415506491
Slightly volatile
Asset Turnover0.03530.03720.1658
Slightly volatile
Gross Profit Margin1.091.141.0109
Slightly volatile
Operating Cycle13.6624.9312.4155
Slightly volatile

Acumen Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap239.5 M252.1 M657.5 M
Slightly volatile
Enterprise Value97.5 M102.6 M613.9 M
Slightly volatile

Acumen Fundamental Market Drivers

Cash And Short Term Investments243.5 M

Acumen Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Acumen Pharmaceuticals Financial Statements

Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue42.3 M44.4 M
Stock Based Compensation To Revenue 0.10  0.08 
Sales General And Administrative To Revenue 0.85  0.59 
Research And Ddevelopement To Revenue 5.01  4.25 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(6.34)(6.65)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY